Skip to main content

Krystal Biotech to Present at Upcoming Scientific Conferences

Written by Customer Service on . Posted in Public Companies.

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.

Presentation details are outlined below.

American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting
Invited Oral Presentation

  • Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
  • Presenter: Trevor Parry, PhD
  • Date and Time: May 17, 2025 at 8:50AM CT

2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster Presentation

  • Title: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
  • Presenter: Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
  • Date and Time: June 2, 2025 from 1:30PM to 4:30PM CT
  • Poster Session or Category: Developmental Therapeutics – Immunotherapy
  • Abstract Number: 2575
  • Poster Bd Number: 222

Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Poster Presentation

  • Title: Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
  • Presenter: Haley Cartwright, PhD
  • Date and Time: May 5, 2025 from 3:00PM to 4:45PM MT
  • Poster Session or Category: 258 – Preclinical Therapeutics
  • Poster Number: B0154

Society for Investigative Dermatology (SID) 2025 Annual Meeting
Poster Presentation

  • Title: Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
  • Presenter: Bruce Nmezi, PhD
  • Date and Time: May 9, 2025 from 4:30PM to 6:00PM PT
  • Poster Session or Category: Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
  • Poster Number: 0554

Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.